GLP-2/TR-10mg

A purified lyophilized material intended exclusively for analytical and laboratory use.

Applications: In-vitro and non-clinical investigative systems.

Form: Freeze-dried powder (10mg)

🔬 Tirzepatide — Overview

GLP-2 T (tirzepatide) is a dual agonist that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, amplifying the effects of both incretin hormones. This dual action enhances insulin secretion, reduces glucagon levels, and improves glucose regulation more effectively than single-pathway agonists. Additionally, Tirz influences metabolic signaling pathways to support energy balance and lipid metabolism, contributing to improved nutrient processing and storage

📌 Brief Functional Description

• Dual GIP/GLP-1 receptor agonist: tirzepatide stimulates both incretin pathways to enhance insulin secretion, suppress glucagon in a glucose-dependent manner, slow gastric emptying, and reduce appetite.

🧪 Chemical & Structural Information

🔢 CAS Number

• 2023788-19-2 — the registered Chemical Abstracts Service number for tirzepatide.

🧬 Molecular Formula

• C225H348N48O68 — elemental formula for the full peptide conjugate incorporating modifications and lipid moiety.

⚖️ Molecular Weight

• Approximately 4,810–4,813 g/mol (Da) — the calculated peptide molecular weight including all modifications.

🧬 Structure & Sequence Features

• Length: Tirzepatide is a 39-amino-acid linear peptide.
• Modifications: It contains non-coded amino acids (α-aminoisobutyric acid [Aib]) at positions 2 and 13 to resist enzymatic degradation, a C-terminal amide, and a C20 fatty diacid (eicosanedioic acid) moiety attached via a hydrophilic linker at a lysine residue (position 20) to promote albumin binding and extend half-life.
• Design: Based on the native GIP sequence with modifications that confer GLP-1 receptor activity and metabolic stability.
• General schematic: “H-Tyr-{Aib}-Glu-Gly-Thr-…-Pro-Ser-NH₂” with the fatty acid side chain linked to a lysine within the sequence.

(A full IUPAC name is very long due to peptide length and modifications, but detailed sequence listings can be found in chemical databases.)

🧠 Mechanism & Research Context

• Dual incretin action: tirzepatide’s balanced activation of GIP and GLP-1 receptors synergistically enhances glucose-dependent insulin secretion and improves metabolic outcomes compared with single-target agents like GLP-1 analogs alone.
• The fatty acid acylation and α-aminoisobutyric acid substitutions contribute to protease resistance and increased albumin binding, prolonging systemic circulation and allowing once-weekly dosing in studies
• Clinical efficacy: robust reductions in HbA1c and body weight have been demonstrated in pivotal clinical trials versus other agents.

⚠️ Safety & Regulatory Notes

• Pharmacokinetics: long half-life (~5 days) due to structural modifications.

🧪 Quick Reference

Notice: Research Use Only. Not for human or veterinary use.